Gut Microbiota in Kidney Disease: Potential Mechanisms and Therapeutic Strategies

A special issue of Nutrients (ISSN 2072-6643). This special issue belongs to the section "Prebiotics and Probiotics".

Deadline for manuscript submissions: 25 September 2024 | Viewed by 1081

Special Issue Editors


E-Mail Website
Guest Editor
Department of Gastroenterological Surgery and Transplantology, Centre of Postgraduate Medical Education, Marymoncka St. 99/103, 01-813 Warsaw, Poland
Interests: chronic kidney disease; dialysis; transplantation; diabetes; vitamins; liver; pancreas
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Human Nutrition and Metabolomics, Pomeranian Medical University in Szczecin, 71-460 Szczecin, Poland
Interests: nutrition; inflammation; metabolism; diabetes; microbiome; short-chain fatty acids; vitamins
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Chronic kidney disease (CKD) is expected to become one of the leading causes of death worldwide due to a lack of access to appropriate methods for diagnosing and treating kidney disease. As a chronic disease, it inevitably leads to a deterioration in the patient's quality of life and malnutrition.

Intestinal microflora has been associated with the development of obesity, metabolic syndrome, and the onset of type 2 diabetes. Untreated diabetes may lead to impaired kidney function. A promising approach to diabetes-related diseases focuses on modulating the intestinal microflora using prebiotics, probiotics, synbiotics, and transplantation of fecal microorganisms. Therefore, in this Special Issue, we focus on the role of intestinal microflora in chronic kidney disease. Our spectrum of interests also includes other kidney diseases.

Microorganisms may play a role in the pathogenesis and prevention of kidney stones, which is problematic as it facilitates the participation of the intestinal microbiome, the impact of antibiotics, and the role of probiotics. Randall's plaques are considered a source of calcium oxalate stone formation. However, the microbiome, including nanobacteria, urease-producing bacteria, and intestinal microflora, influence urological health. Therefore, we invite articles investigating the broadly understood impact of the microbiome, both negative and positive, on the course of diseases related to kidney dysfunction.

Dr. Karolina Kędzierska-Kapuza
Prof. Dr. Małgorzata Szczuko
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nutrients is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chronic kidney disease
  • intestinal microflora
  • prebiotics
  • probiotics
  • synbiotics
  • the atransplantation of fecal microorganisms

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 1639 KiB  
Article
Changes in the Progression of Chronic Kidney Disease in Patients Undergoing Fecal Microbiota Transplantation
by Giovanna Yazmín Arteaga-Muller, Samantha Flores-Treviño, Paola Bocanegra-Ibarias, Diana Robles-Espino, Elvira Garza-González, Graciela Catalina Fabela-Valdez and Adrián Camacho-Ortiz
Nutrients 2024, 16(8), 1109; https://0-doi-org.brum.beds.ac.uk/10.3390/nu16081109 - 10 Apr 2024
Viewed by 913
Abstract
Chronic kidney disease (CKD) is a progressive loss of renal function in which gut dysbiosis is involved. Fecal microbiota transplantation (FMT) may be a promising alternative for restoring gut microbiota and treating CKD. This study evaluated the changes in CKD progression in patients [...] Read more.
Chronic kidney disease (CKD) is a progressive loss of renal function in which gut dysbiosis is involved. Fecal microbiota transplantation (FMT) may be a promising alternative for restoring gut microbiota and treating CKD. This study evaluated the changes in CKD progression in patients treated with FMT. Patients with diabetes and/or hypertension with CKD clinical stages 2, 3, and 4 in this single-center, double-blind, randomized, placebo-controlled clinical trial (NCT04361097) were randomly assigned to receive either FMT or placebo capsules for 6 months. Laboratory and stool metagenomic analyses were performed. A total of 28 patients were included (15 FMT and 13 placebo). Regardless of CKD stages, patients responded similarly to FMT treatment. More patients (53.8%) from the placebo group progressed to CKD than the FMT group (13.3%). The FMT group maintained stable renal function parameters (serum creatinine and urea nitrogen) compared to the placebo group. Adverse events after FMT treatment were mild or moderate gastrointestinal symptoms. The abundance of Firmicutes and Actinobacteria decreased whereas Bacteroidetes, Proteobacteria and Roseburia spp. increased in the FMT group. CKD patients showed less disease progression after FMT administration. The administration of oral FMT in patients with CKD is a safe strategy, does not represent a risk, and has potential benefits. Full article
Show Figures

Figure 1

Back to TopTop